Zibor 3500 (Bemiparin sodium) is commonly used as an anticoagulant to manage conditions related to blood clot formation. This medication is applied across domains where supportive symptom management and maintenance of physiological stability are needed.

The therapeutic benefit is relevant in conditions associated with acute or disruptive episodes, focusing on the management of symptoms related to systemic imbalance, such as the risks linked to Deep Vein Thrombosis (DVT), established DVT manifestations, and support for procedures like hemodialysis. The medication may assist with managing the risk of developing a DVT, which can contribute to easing the symptoms related to physical discomfort (like noticeable swelling) and the likelihood of severe complications.

“The primary benefit helps to provide support against the physiological strain caused by conditions marked by increased physiological stress.”

---

Quick Fact: Support for Symptomatic Periods
Zibor helps patients by managing risks associated with established DVT, which contributes to easing the overall symptom load and supports functional stability during treatment.

Regulatory References

1. Health Products Regulatory Authority (HPRA) Summary of Product Characteristics

The use of Zibor 3500 (Bemiparin sodium) is strictly governed by population-specific rules defined in official regulatory documents. Eligibility is determined by age, physiological status, and the presence of certain high-risk medical conditions.

---

Eligibility Status by Population

Classification	Population Group	Regulatory Status
Allowed	Adults and Older Adults (Geriatric)	Permitted (No dose adjustment for older adults)
Conditional	Mild/Moderate Renal Impairment ( CrCl 30-80 mL/min)	Permitted with close monitoring
Not Recommended	Children (Pediatric)	Safety and efficacy not established
Not Recommended	Pregnancy and Lactation	Safety and efficacy not established

---

Contraindications (Absolute Non-Eligibility)

Zibor 3500 is strictly contraindicated in patients with a history of confirmed or suspected Heparin-Induced Thrombocytopenia (HIT), or a known hypersensitivity to the drug or substances of porcine origin. Absolute prohibitions also apply to patients with active hemorrhage, a significant risk of bleeding, or severe impairment of liver or pancreatic function. Use is also prohibited if high-risk lesions are present, such as an active peptic ulcer or a hemorrhagic stroke, as well as in cases of acute bacterial endocarditis.

The official regulatory documents for Zibor 3500 (Bemiparin sodium) define its interaction profile primarily around agents that affect hemostasis and serum potassium levels. No medicinal products are formally designated as contraindicated (prohibited) based on drug-drug interaction.

Pharmacodynamic Interactions (Increased Bleeding Risk)

Co-administration with several medicinal product categories is not advisable due to an increased risk of bleeding. This pharmacodynamic effect results from additive interference with the body’s coagulation or platelet function. Agents noted in regulatory documents include:

• Vitamin K antagonists (e.g., warfarin, acenocoumarol)
• Platelet inhibitors (e.g., aspirin, ticlopidine, clopidogrel)
• Non-steroidal anti-inflammatory drugs (NSAIDs) and other salicylates
• Systemic glucocorticoids and Dextran (for plasma volume expansion)

Hyperkalaemia and Efficacy Alterations

Like other low molecular weight heparins, Bemiparin may suppress adrenal secretion of aldosterone, potentially leading to hyperkalaemia (elevated plasma potassium levels). Co-administration with medicines that increase serum potassium, such as certain diuretics or anti-hypertensives, requires especially careful medical supervision. This risk is particularly observed in patient populations with chronic renal failure or diabetes mellitus. Additionally, regulatory information notes that Intravenous nitroglycerine may result in a decrease in the drug's anticoagulant efficacy.

Timing-Based Administration Constraints

A specific timing-based condition is required for patients undergoing regional anesthesia. The subsequent dose of Bemiparin sodium must not be administered until at least four hours after a spinal or epidural catheter has been removed.

How Zibor 3500 Works

Zibor 3500 (Bemiparin sodium) functions as an Ultra-Low Molecular Weight Heparin (Ultra-LMWH). Its action is purely focused on modulating the enzymatic steps of the coagulation cascade, defined by its small size, which dictates a highly selective interaction profile directly in the bloodstream.

Targeted Potentiation of Antithrombin III (ATIII)

The mechanism involves the drug binding to the endogenous inhibitor protein, Antithrombin III (ATIII). This interaction induces a conformational change in the ATIII structure, which amplifies its inhibitory action. This domain establishes the core catalytic step preceding all subsequent molecular effects.

Selective Factor Xa Inhibition and Thrombin Suppression

The activated ATIII complex targets and rapidly inactivates Factor Xa (FXa), the enzyme responsible for initiating thrombin generation. By selectively blocking Factor Xa, the drug interrupts the common coagulation pathway, suppressing the systemic generation of thrombin. The resulting physiological consequence is the suppression of fibrin mesh formation, which establishes an antithrombotic state.

Mechanistic Constraint of Chain Length

Bemiparin sodium's short molecular length is a defining feature that constrains its mechanism; the molecule is too short to simultaneously bridge and inhibit Factor IIa (Thrombin) and ATIII. This structural limitation promotes its high selectivity for FXa (Anti-Xa:Anti-IIa ratio approx 8:1), which defines its mechanistic profile.

Administration Overview

Zibor 3500 is typically administered via subcutaneous injection. This method involves delivering the medication into the fatty tissue layer located just beneath the skin. Proper administration is essential to ensure the medication is absorbed correctly and to minimize the risk of local irritation at the injection site.

Preparation for Use

Before administration, the medication should be inspected. The solution inside the pre-filled syringe should be clear and colorless or slightly yellowish. If the solution appears cloudy or contains visible particles, it should not be used.

It is important to select an appropriate injection site, commonly the abdominal area, alternating between the left and right sides with each application. The area should be cleaned thoroughly before proceeding.

Injection Technique

The injection process involves a specific technique to ensure the needle enters the subcutaneous layer correctly. This usually involves pinching a fold of skin between the thumb and forefinger and inserting the needle perpendicularly into the skin fold. The plunger should be depressed steadily until the entire dose is delivered.

After the needle is withdrawn, it is advised not to rub the injection site, as this can increase the likelihood of bruising or minor local reactions.

Handling and Storage

Pre-filled syringes are designed for single use only. Once a dose has been administered, the syringe must be disposed of according to local protocols for sharps and biohazardous waste. The medication should be stored in its original packaging to protect it from light and maintained at the temperature conditions specified by the manufacturer.

Research Evidence / Overview of Studies

Research Summary

Research has explored the role of the compound, Zibor 3500 (bemiparin sodium), in the management of thrombotic disorders. Studies have evaluated whether the compound's use was associated with changes in coagulation markers and clinical outcomes in various patient populations. Zibor 3500 is a low molecular weight heparin (LMWH) with a mean molecular weight of 3600 Da.

Key Findings in Phase III Trials

Monotherapy: Prevention of Venous Thromboembolism (VTE)

• Orthopedic Surgery (High Risk): Two randomized, placebo-controlled trials examined whether the compound's use in a 3500 IU daily dose was associated with differences in the incidence of VTE compared to control groups (unfractionated heparin or placebo). One key study reported that the rate of VTE and deep vein thrombosis (DVT) were statistically different between the compound group and the unfractionated heparin group following total hip replacement surgery.
• Tolerability Assessment: Two trials included a protocol for observing participant well-being over the study duration. These findings documented participant response and adherence over the study duration, noting that the compound was generally tolerated.

Combination Therapy: Treatment of Established DVT

• Outcomes Comparison: Early trials examined whether treatment with the compound (at doses up to 10,000 IU/day) was associated with different outcomes compared to unfractionated heparin for the short-term treatment of acute DVT. Studies assessed whether there was a reduction in thrombus size over the study period.
• Long-Term Management: Subsequent trials examined the use of Zibor 3500 IU daily compared to oral warfarin for the long-term (12-week) management of DVT, concluding that the results of the comparison were inconsistent across available studies. The relative effect of the combined approach compared to single-agent therapy remains under examination.

Common questions about Zibor 3500 (FAQ)

---

Q: Is Zibor 3500 the same as other medicines for the same condition?

A: Zibor 3500 contains the active substance Bemiparin sodium, which is classified as an Ultra-Low Molecular Weight Heparin (Ultra-LMWH). Official documents describe it as having the lowest mean molecular weight (approximately 3,600 Daltons) among LMWHs and a distinct ratio of anti-clotting activity (anti-Factor Xa to anti-Factor IIa ratio of about 8:1). These specific characteristics define its profile compared to other LMWH medicines.

---

Q: How quickly does Zibor 3500 usually start to work?

A: According to official prescribing information, the peak activity of Zibor 3500 in the plasma is reached within approximately two to four hours after it is administered. This measurement describes when the concentration of the medicine's activity is generally highest in the blood.

---

Q: What is the difference between Zibor 3500 and Zibor 1500?

A: The difference between Zibor 3500 and other Zibor products, such as Zibor 1500, lies in the strength of the dose unit, measured in International Units (IU). Different strengths are licensed for different clinical purposes and may be based on factors like the patient's weight or the specific medical procedure being managed.

---

Q: Can Zibor 3500 be stopped suddenly?

A: Official documents recommend consulting a healthcare professional regarding any decision to change the treatment schedule or discontinue the medicine. Regulatory patient information advises against stopping the use of Zibor 3500 abruptly without professional guidance.

---

Q: What should I know about taking Zibor 3500 with alcohol?

A: Official prescribing information focuses on medicinal products that may increase the risk of bleeding. As Zibor 3500 is an anticoagulant (blood thinner), caution is generally advised with any substance that may affect the body's ability to clot. This is a topic that should be reviewed with a healthcare professional.

---

Q: What time of day is Zibor 3500 typically recommended to be taken?

A: The required frequency for Zibor 3500 is typically once daily. The specific time of day for administration is not rigidly defined in regulatory documents. The time is typically determined by the prescriber as part of the personalized treatment plan.

---

Q: Can Zibor 3500 be taken with common pain relievers?

A: Regulatory documents explicitly warn that co-administration is generally not advised with certain classes of pain relievers due to an increased risk of bleeding. This includes Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), other salicylates, and platelet inhibitors.

---

Q: What are the long-term effects of taking Zibor 3500?

A: Official prescribing information notes that one specific risk may increase with the duration of therapy: elevated potassium levels (hyperkalaemia). Regular monitoring of serum electrolytes is recommended for patients at risk if the treatment is prolonged beyond seven days.

---

Q: What happens if Zibor 3500 doesn't seem to be helping?

A: If there are any concerns about the effectiveness or use of the medicine, regulatory patient information directs the individual to consult their prescribing doctor. This consultation allows a qualified professional to address any concerns regarding the medicine’s use.

---

Q: Why is Zibor 3500 sometimes prescribed for reasons not mentioned on the label?

A: Zibor 3500 is officially licensed only for its regulatory-approved indications, which include the prevention of blood clots (thromboembolic disease) in specific patient populations, such as those undergoing orthopedic surgery. The information provided in official documentation is strictly limited to these approved uses.

---

Q: Can Zibor 3500 be used while breastfeeding?

A: Official regulatory documents indicate that the use of Zibor 3500 is not recommended for women who are breastfeeding. This is because the safety and efficacy of the medicine for the child during lactation have not been definitively established in regulatory documents.

---

Q: How long does Zibor 3500 stay in the body after the last use?

A: The elimination half-life of Zibor 3500, which is the time it takes for the concentration of the medicine to be reduced by half, is approximately five to six hours after it is administered.

---

Q: Is there a generic version of Zibor 3500 available?

A: The active substance in Zibor 3500 is Bemiparin sodium, which is the non-proprietary or generic name for the compound. Zibor is the specific brand name under which this Bemiparin sodium product is marketed by the manufacturer.

---

Q: Does Zibor 3500 work for all people who take it?

A: Clinical trials have examined the effectiveness of Zibor 3500 in specific patient populations, reporting outcomes in these settings. As with any medicine, the body's response is individual, and an effect cannot be guaranteed for every person.

How to Store and Dispose of Zibor 3500?

This medication must be stored according to regulatory requirements to ensure its stability and effectiveness. Official labeling strictly defines the necessary environmental controls and the proper methods for disposal.

Storage Requirement	Official Condition
Temperature Limit	Store below 25 C
Prohibited Condition	Do not freeze
Expiry	Do not use after the official expiry date (EXP)

For safety, the single-use solution must be kept out of the sight and reach of children. The used pre-filled syringe must be discarded immediately into a sharps bin. It is mandatory that Zibor 3500 and any unused medicine not be thrown away via household waste or wastewater; a pharmacist can provide guidance on proper disposal.